36 trials (keyword fallback)
Breast Cancer · Drug/Agent Toxicity by Tissue/Organ · Unspecified Adult Solid Tumor, Protocol Specific
Primary: To Determine Whether the Prophylactic Use of a Topical Urea/Lactic Acid Cream Can Decrease the Incidence/Severity of Capecitabine-caused Palmar-plantar…
Metabolic Acidosis · Chronic Kidney Disease
Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD
Epilepsy
Primary: Salivary Lactic Acid Levels With Seizures — 8.16 mmol/L
Muscle Loss · Fractures · Osteoporosis, Age Related
Primary: The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide — 240; 230; 241; -53 nmol/day
Buttocks Volume Loss
Primary: Change From Baseline in Buttocks Volume 6 Months After Treatment — 22.21 cm^3 — p=<0.0001
Intra-Abdominal Hypertension · Inguinal Hernia
Primary: Intraabdominal Pressure — 25.58 mmHg
Wrinkles in Decolletage
Primary: Percentage of Responders on the Galderma Décolletage Scale (GDS), as Assessed Live by the Treating Investigator, at Month 9 — 93.8; 78.6 percentage of Participants
Signs and Symptoms, Digestive
Primary: Modification of the Composition of the Intestinal Microflora: Bifidobacterium — 7.88; 7.60; 8.13; 8.10 log10 CFU/g — p=<0.05
Wrinkle
Primary: Change From Baseline in the Nasolabial Folds Severity Score on the Wrinkle Severity Rating Scale (WSRS) 6 Months After Treatment — -0.3; -0.2; -0.1 score on a scale
Facial Volume Loss
Primary: Mean Subject Self Reported Quality of Life Scale — 3.45 units on a scale
Diabetes Mellitus · Lactic Acidosis
Primary: Incidence of Lactic Acidosis — 0; 0 participants
MELAS · LHON · Leigh Syndrome
Primary: SAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF) — 386.2; 395.0; 385.8; 399.3 msec
Septic Shock
Primary: Lactate Level 24 Hours After the First Study Medication Dose — 2.6; 2.5 mmol/L — p=0.40
MELAS Syndrome
Primary: Mean Change in Cerebral Lactate Concentration (as Measured by Magnetic Resonance Spectroscopy) — -0.09; 0.16; -0.49 IU
MELAS Syndrome
Primary: Clinical Safety of TIV Vaccine — 4; 0; 0; 0 Participants